Headquartered in Denver, CO Fiscal year ends December NASDAQ: PALI palisadebio.com
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated and fibrotic diseases.
Its lead and sole disclosed program is PALI-2108, an investigational once-daily oral PDE4 inhibitor prodrug. The drug is designed for localized bioactivation in the terminal ileum and colon. Its active metabolite, PALI-0008, inhibits PDE4 isoforms A, B and D, raising intracellular cAMP to modulate inflammatory signaling.
PALI-2108 is in Phase 2 development for inflammatory bowel disease:
- The global Phase 2b ASCENTRA-UC trial in moderately to severely active ulcerative colitis dosed its first patient in October 2026.
- The Phase 2a ASCENTRA-CD trial in moderate-to-severe Crohn's disease received FDA IND clearance in September 2026, with enrollment targeted for Q1 2027.
The company generates no product revenue. It has recorded occasional license revenue ($500 thousand in the first nine months of 2026) and funds operations mainly through equity financing. It held $113.6 million in cash at September 30, 2026, which management expects to fund operations through key Phase 2 readouts in Q4 2027 and Q1 2028. Updated
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower…
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated and fibrotic diseases. Its lead and sole disclosed program is PALI-2108, an investigational once-daily oral PDE4 inhibitor prodrug.
The Wall Street consensus 12-month price target for PALI is $8.90.
